Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Mar;38(3):616-9.
doi: 10.1128/AAC.38.3.616.

Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model

L D Condreay  1 , R W Jansen, T F Powdrill, L C Johnson, D W Selleseth, M T Paff, S M Daluge, G R Painter, P A Furman, M N Ellis, et al.
Affiliations

Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model

L D Condreay et al. Antimicrob Agents Chemother. 1994 Mar.

Abstract

A murine model was developed to investigate the in vivo activity of anti-hepatitis B virus (HBV) agents. Mice with subcutaneous tumors of HBV-producing 2.2.15 cells showed reductions in levels of HBV in serum and in intracellular levels of HBV when the mice were orally dosed with (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC). No effects on tumor size or alpha-fetoprotein levels were observed. FTC can selectively inhibit HBV replication at nontoxic doses.

PubMed Disclaimer

References

    1. Science. 1980 Jul 25;209(4455):497-9 - PubMed
    1. J Hepatol. 1993;17 Suppl 3:S137-42 - PubMed
    1. FEBS Lett. 1985 Apr 22;183(2):219-22 - PubMed
    1. Cancer Res. 1985 Sep;45(9):4322-9 - PubMed
    1. Gastroenterology. 1986 Oct;91(4):818-24 - PubMed